收费全文 | 687篇 |
免费 | 16篇 |
财政金融 | 179篇 |
工业经济 | 57篇 |
计划管理 | 121篇 |
经济学 | 104篇 |
综合类 | 1篇 |
运输经济 | 10篇 |
旅游经济 | 28篇 |
贸易经济 | 127篇 |
农业经济 | 31篇 |
经济概况 | 45篇 |
2024年 | 1篇 |
2023年 | 4篇 |
2021年 | 6篇 |
2020年 | 8篇 |
2019年 | 11篇 |
2018年 | 11篇 |
2017年 | 11篇 |
2016年 | 24篇 |
2015年 | 5篇 |
2014年 | 30篇 |
2013年 | 124篇 |
2012年 | 20篇 |
2011年 | 38篇 |
2010年 | 33篇 |
2009年 | 37篇 |
2008年 | 25篇 |
2007年 | 29篇 |
2006年 | 22篇 |
2005年 | 15篇 |
2004年 | 26篇 |
2003年 | 23篇 |
2002年 | 25篇 |
2001年 | 9篇 |
2000年 | 19篇 |
1999年 | 15篇 |
1998年 | 12篇 |
1997年 | 13篇 |
1996年 | 10篇 |
1995年 | 10篇 |
1994年 | 13篇 |
1993年 | 9篇 |
1992年 | 6篇 |
1991年 | 6篇 |
1990年 | 5篇 |
1989年 | 2篇 |
1988年 | 4篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 7篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1982年 | 3篇 |
1981年 | 3篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1973年 | 1篇 |
Telaprevir (T, TVR) is a direct-acting antiviral (DAA) used for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection. The sustained virological response (SVR) rates, i.e., undetectable HCV RNA levels 24 weeks after the end of treatment, is what differentiate treatments. This analysis evaluated the cost-effectiveness of TVR combined with pegylated interferon (Peg-IFN) alfa-2a plus ribavirin (RBV), with Peg-IFN and RBV (PR) alone or with boceprevir (B, BOC) plus Peg-IFN alfa-2b and RBV, in naïve patients.
Methods:
A Markov cohort model of chronic HCV disease progression reflected the pathway of naïve patients initiating anti-HCV therapy. SVR rates were derived from a mixed-treatment comparison including results from Phase II and III trials of TVR and BOC, and trials comparing both PR regimens. SVR has significant impact on survival, quality-of-life, and costs. Incremental cost per life year (LY) gained and quality-adjusted-life-year (QALY) gained were computed at lifetime, adopting the (National Health Service) NHS perspective. Cost and health outcomes were discounted at 3.5%. Uncertainty was assessed using deterministic and probabilistic sensitivity analyses. Sub-group analyses were also performed by interleukin (IL)-28B genotype and fibrosis stage.
Results:
Higher costs and improved outcomes were associated with T/PR relative to PR alone, resulting in an ICER of £12,733 per QALY gained. T/PR retained a significant SVR advantage over PR alone and was cost-effective regardless of IL-28B genotype and fibrosis stages. T/PR regimen ‘dominated’ B/PR, generating 0.2 additional QALYs and reducing lifetime cost by £2758. Sensitivity analyses consistently resulted in ICERs less than £30,000/QALY for the T/PR regimen over PR alone.
Limitations:
No head-to-head trial provides direct evidence of better efficacy of T/PR vs B/PR.
Conclusion:
The introduction of TVR-based therapy for genotype 1 HCV patients is cost-effective for naïve patients at the £30,000 willingness-to-pay threshold, regardless of IL-28B genotype or fibrosis stage. 相似文献